Cargando…
Management of patients with intermediate stage hepatocellular carcinoma
Hepatocellular carcinoma (HCC) causes a significant health burden globally and its impact is expected to increase in the coming years. Intermediate stage HCC, as defined by the Barcelona Clinic Liver Cancer (BCLC) system stage B, represents up to 30% of patients at diagnosis and encompasses a broad...
Autores principales: | Prince, David, Liu, Ken, Xu, Weiqi, Chen, Minjiang, Sun, Jin-Yu, Lu, Xiao-Jie, Ji, Jiansong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649909/ https://www.ncbi.nlm.nih.gov/pubmed/33224278 http://dx.doi.org/10.1177/1758835920970840 |
Ejemplares similares
-
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
por: Xu, Weiqi, et al.
Publicado: (2019) -
Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019) -
Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization
por: Lee, Hsin-Lun, et al.
Publicado: (2019) -
Single nucleotide polymorphisms in telomere length-related genes are associated with hepatocellular carcinoma risk in the Chinese Han population
por: Huang, Peng, et al.
Publicado: (2020) -
Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
por: Liu, Xuan, et al.
Publicado: (2020)